Table 2.
Univariate and Multivariate Analysis of the Prognostic Factors for OS in All Patients
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Gender | 1.777 (0.126–2.522) | 0.453 | ||
| Male | ||||
| Female | ||||
| Age | 1.408 (0.561–2.512) | 0.655 | ||
| <65 | ||||
| ≥65 | ||||
| Child-Pugh | 0.642 (0.350–6.941) | 0.561 | ||
| A | ||||
| B | ||||
| ECOG-PS | 0.258 (0.430–2.719) | 0.218 | ||
| 0–1 | ||||
| 2 | ||||
| Platelet (10^9/L) | 0.998 (0.994–1.003) | 0.493 | ||
| ≥100 | ||||
| <100 | ||||
| Total bilirubin (µmol/L) | 0.981 (0.934–1.031) | 0.457 | ||
| ≥34 | ||||
| <34 | ||||
| Albumin (g/L) | 1.003 (0.895–1.124) | 0.956 | ||
| ≥35 | ||||
| <35 | ||||
| ALT (IU/L) | 0.908 (0.511–1.495) | 0.704 | ||
| ≥40 | ||||
| <40 | ||||
| AST (IU/L) | 0.737 (0.390–1.393) | 0.347 | ||
| ≥40 | ||||
| <40 | ||||
| ALBI grade | 1.051 (0.598–1.757) | 0.929 | ||
| ≥2 | ||||
| 1 | ||||
| AFP (ng/mL) | 0.300 (0.291–1.033) | 0.063 | ||
| ≥400 | ||||
| <400 | ||||
| Maximum tumor size (cm) | 0.543 (0.267–2.034) | 0.556 | ||
| ≥5 | ||||
| <5 | ||||
| Anti-PD-1 antibodies | 1.726 (0.267–3.864) |
0.732 | ||
| Sintilimab | ||||
| Tislelizumab | ||||
| Camrelizumab | ||||
| Tumor number | 1.910 (0.906–4.027) | 0.089 | ||
| Solitary | ||||
| Multiple | ||||
| Operation | 3.731 (1.038–13.407) | 0.044 | 3.731 (1.038–13.407) | 0.044 |
| Yes | ||||
| No | ||||
| Extrahepatic metastasis | 2.837 (0.327–4.583) | 0.344 | ||
| Yes | ||||
| No | ||||
Note: Bold values is to highlight the meaningful p-values.
Abbreviations: OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ALT, alanine transaminase; AST, aspartate transaminase; ALBI, albumin-bilirubin; AFP, ɑ-fetoprotein; HBsAg, hepatitis B surface antigen.